Introduction: Cervical Cancer is 4th most common cancer among females. Globally with 604,000 new cases and 342,000 deaths reported annually according to 2020 data. About 90% death occurred in low and Middle-income countries by carcinoma cervix. Concurrent chemoradiation combined with brachytherapy is the standard of care in locally advanced carcinoma cervix.

Method: The aim is to study the dose distribution and advantage of VMAT with conventional radiotherapy. Randomized comparative perspective study in which we have included 60 patients. A total of 60 patients were included and analyzed for disease status at the end of treatment.

Result: No significant differences observed in Dmax, D95, CI, and HI values. VMAT with Rapid Arc plan showed reduced OAR doses, while 3DCRTFIF exhibited higher Bowel V45Gy compared to VMAT with Rapid Arc plan. In our study, Rapid arc shown lower dose to bladder as compart to 3DCRT at D15 49.6 Gy Vs-51.1, D30 48.7 Gy vs 50.7 Gy, D50 46.8 Gy vs 50.4 Gy. Bone marrow toxicity was 10% (9) lesser in VMAT arm as compared to 3D CRT. Some observational studies shown hematological toxicities were higher when used with combination of chemotherapy as compared to EBRT alone (27). 3DCRT patients’ median absolute volume was twice received 40 Gy than 3 VMAT. Sometimes it resulted in interruption and delay of treatment time exceeded 52 days causes loss of local treatment and decreases overall survival approximately 1% per day.

Keywords: Volumetric Modulated Arc Therapy; Intensity-Modulated Radiation Therapy; Carcinoma Cervix

References

1. World Health Organization. Cervical cancer (2018).
2. Perez CA and Kavanagh BD. “Uterine cervix”. In: Helperin EC, Perez CA, Brady LW, editors. Perez and Brady’s Principles and Practices of Radiation oncology, 5th ed Philadelphia: Lippincott Williams & Wilkins; (2008): 1593-1595.
3. Kirwan JM., et al. “A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer”. Radiotherapy Oncology 68 (2003): 217-226.
4. Kurrumeli D., et al. “An easy way to determine bone mineral density and predict pelvic insufficiency fractures in patients treated with radiotherapy for cervical cancer”. Strahlentherapie und Onkologie (2020).
5. Osann K., et al. “Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials”. Gynecology and Oncology 135 (2014): 266-272.
6. de Boer P., et al. “Target tailoring and proton beam therapy to reduce small bowel dose in cervical cancer radiotherapy: a comparison of benefits”. Strahlentherapie und Onkologie 194 (2018): 255-263.
7. Bortfeld T. “IMRT: a review and preview”. Physics in Medicine and Biology 51 (2006): R363-R379.
8. Otto K. “Volumetric modulated arc therapy: IMRT in a single gantry arc”. Medical Physics 35 (2008): 310-317.
9. Folkert MR., et al. “Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate - and high-risk cervical cancer”. Gynecology and Oncology 128 (2013): 288-293.
10. Gandhi AK., et al. “Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study”. International Journal of Radiation Oncology, Biology, Physics 87 (2013): 542-548.
11. Chen MF., et al. “Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy”. International Journal of Radiation Oncology, Biology, Physics 67 (2007): 1438-1444.
12. Hasselle MD., et al. “Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix”. International Journal of Radiation Oncology, Biology, Physics 80 (2011): 1436-1445.
13. Cozzi L., et al. “A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy”. Radiotherapy Oncology 89 (2008): 180-191.
14. Sharfo AW., et al. “Comparison of VMAT and IMRT strategies for cervical cancer patients using automated planning”. Radiotherapy Oncology 114 (2015): 395-401.
15. Guy JB., et al. “Dosimetric study of volumetric arc modulation with RapidArc and intensity-modulated radiotherapy in patients with cervical cancer and comparison with 3-dimensional conformal technique for definitive radiotherapy in patients with cervical cancer”. Medical Dosimetry 1 (2016): 9-14.
16. Erpolat OP., et al. “Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: A national multi-center study”. European Journal of Gynaecological Oncology 1 (2014): 62-66.
17. Lim K., et al. “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer”. International Journal of Radiation Oncology, Biology, Physics2 (2011): 348-355.
18. Loiselle C and Koh WJ. “The emerging use of IMRT for treatment of cervical cancer”. Journal of the National Comprehensive Cancer Network12 (2010): 1425-1434.
19. Lin Y., et al. “Clinical outcomes of volumetric modulated arc therapy following Intracavitary/interstitial Brachytherapy in cervical cancer: a single institution retrospective experience”. Frontiers in Oncology 9 (2019): 760.
20. Renard-Oldrini S., et al. “Dosimetric comparison between the intensity modulated radiotherapy with fixed field and Rapid Arc of cervix cancer”. Cancer Radiotherapy 16 (2012): 209-214.
21. Gallagher MJ., et al. “A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation”. International Journal of Radiation Oncology, Biology, Physics 12 (1986): 1565-1573.
22. Emami B. “Tolerance of normal tissue to therapeutic radiation”. Reports of Radiotherapy and Oncology 1 (2013): 25-48.
23. Roszak A., et al. “Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy”. 17 (2012): 332-338.
24. Vandecasteele K., et al. “Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome”. Strahlentherapie und Onkologie 188 (2012): 576-581.
25. Chakraborty S., et al. “How well do elderly patients with cervical cancer tolerate definitive radiochemotherapy using RapidArc? Results from an institutional audit comparing elderly versus younger patients”. Ecancer 8 (2014): 484.
26. Lin Y., et al. “Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis”. Radiation Oncology1 (2018): 177.
27. Dearnaley DP., et al. “Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: a randomized trail”. Lancet 23 (1999): 267-272.
28. Girinsky T., et al. “Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome”. International Journal of Radiation Oncology, Biology, Physics5 (1993): 1051-1056.
29. Roeske JC., et al. “Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies”. International Journal of Radiation Oncology, Biology, Physics5 (2000): 1613-1621.
30. Mell LK., et al. “Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: An international multicenter phase II clinical trial (INTERTECC-2)”. International Journal of Radiation Oncology, Biology, Physics 3 (2017): 536-545.
31. Yeung AR., et al. “Improvement in patient-reported outcomes with intensity-modulated radiotherapy (RT) compared with standard RT: A report from the NRG oncology RTOG 1203 study”. Journal of Clinical Oncology 15 (2020): 1685-1692.

Citation

Citation: Seema Devi., et al. “Dosimetric Distribution of Vmat Versus 3dcrt in Treatment of Locally Advanced Carcinoma Cervix”.Acta Scientific Cancer Biology 8.8 (2024): 19-26.

Copyright

Copyright: © 2024 Seema Devi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.